Advertisement
Valeant
Subscribe to Valeant

The Lead

Valeant Boosts Offer for Salix Pharma to About $11.11B

March 16, 2015 8:29 am | News | Comments

Valeant is raising its offer for Salix Pharmaceuticals to about $11.11 billion, heating up a bidding fight for the company.

Valeant Faces Another Takeover Battle as Endo Submits Higher Bid for Salix

March 12, 2015 8:07 am | by Ross Marowits, The Canadian Press | News | Comments

Valeant Pharmaceuticals faced another takeover fight Wednesday after Endo International...

Endo Tops Valeant's Offer for Salix

March 11, 2015 3:31 pm | by The Associated Press | News | Comments

Endo International is trying to lure fellow drugmaker Salix Pharmaceuticals with an offer Endo...

Valeant to Buy Salix for Approximately $10B in Cash

February 23, 2015 8:27 am | by ALEX VEIGA, AP Business Writer | News | Comments

Valeant Pharmaceuticals International Inc. has agreed to buy Salix Pharmaceuticals Ltd. for...

View Sample

FREE Email Newsletter

Valeant Raises Offer for Dendreon Assets

February 6, 2015 8:37 am | by The Canadian Press | News | Comments

Valeant Pharmaceuticals International has raised its offer for the Provenge prostate cancer vaccine and other assets of U.S. drugmaker Dendreon Corp. by $100 million to $400 million.            

Dendreon Reaches Agreement for Valeant to Serve as “Stalking Horse Bidder” in Court-Supervised Sales Process

January 30, 2015 8:37 am | News | Comments

Under the terms of the agreement, Valeant would acquire the world-wide rights of PROVENGE® (sipuleucel-T) and certain other Dendreon assets for $296 million, subject to higher and better bids.          

Valeant Pharma Projects Double-Digit Growth in Sales and Earnings Per Share in 2015

January 8, 2015 10:42 am | by The Canadian Press | News | Comments

Valeant Pharmaceuticals says it plans to focus on small to medium-sized acquisitions from privately owned companies in 2015 following an unsuccessful attempt to take over California-based Allergan.         

Advertisement

Valeant Pharmaceuticals Recalls Virazole®

January 2, 2015 8:38 am | News | Comments

Valeant Pharmaceuticals is issuing a voluntarily recall of one lot of Virazole® (ribavirin powder for solution), 100 mL, 6g Vial, 4-pack to the user level. Inhalation of a non-sterile product with microbial contamination into the airways could increase the risk of respiratory infection.

FDA Approves Valeant’s ONEXTON Acne Gel

November 25, 2014 8:13 am | News | Comments

Valeant Pharmaceuticals has received approval from the FDA for ONEXTON Gel (clindamycin phosphate and benzoyl peroxide), 1.2%/3.75%, for the once-daily treatment of comedonal (non-inflammatory) and inflammatory acne in patients 12 and older.  

Allergan Soars on Deal Reports

November 17, 2014 8:11 am | by The Associated Press | News | Comments

Shares of Allergan jumped in premarket trading Monday after several reports surfaced over the weekend that specialty drugmaker Actavis was preparing to buy the maker of Botox, which is embroiled in a takeover battle with Valeant Pharmaceuticals.

Allergan Amends Company’s Bylaws Prior to Stockholder's Meeting

November 12, 2014 8:12 am | News | Comments

Allergan today announced that its Board of Directors has approved amendments to the company’s bylaws that streamline the process associated with calling a special meeting of stockholders. The Board determined to amend the bylaws after meetings with many of the Company’s major stockholders and other governance organizations to solicit their input and perspectives.

Valeant: We'll Bump Allergan Offer to $200 a Share

October 27, 2014 7:33 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals International says it will raise its offer for Botox maker Allergan to $200 or more per share. Valeant made the statement in a letter to Allergan's board released publicly seeking to urge Allergan to talk about an acquisition.

Advertisement

Valeant Considering Higher Bid for Allergan after Reporting Strong Q3 Results

October 20, 2014 1:26 pm | by Ross Marowits, The Canadian Press | News | Comments

Valeant Pharmaceuticals said that its strong third-quarter results and a higher growth forecast give it ammunition to win over reluctant takeover target Botox maker Allergan with an increased bid at the appropriate time.     

Pressure Mounting on Allergan as Proxy Firm ISS Criticizes Board Approach

October 2, 2014 3:52 pm | by Ross Marowits, The Canadian Press | News | Comments

Proxy advisory firm Institutional Shareholder Services has joined several large Allergan shareholders calling for a vote after reports surfaced that it is in talks to buy Salix Pharmaceuticals. The US$10 billion all-cash deal could make it too expensive for Valeant to purchase the company.

Valeant Pharma Expects Third Quarter Revenue to Top Forecasts

September 24, 2014 1:07 pm | by The Associated Press | News | Comments

Shares of Valeant Pharmaceuticals International Inc. climbed Wednesday after the Canadian drugmaker said it expects market share gains in most of its businesses and that its third-quarter revenue will top forecasts.      

Pershing Capital Threatens to Sue Allergan if it Acquires Salix Without Vote

September 23, 2014 2:40 pm | by Ross Marowits, The Canadian Press | News | Comments

Allergan's largest shareholder, Pershing Square Capital, has threatened to sue the Botox maker if it attempts to buy Salix Pharmaceuticals without holding a shareholder vote. The investment fund headed by Bill Ackman has teamed up with Valeant Pharmaceuticals to make a $50-billion hostile takeover bid for Allergan.

Allergan Agrees to Move Forward with Meeting

September 16, 2014 6:44 am | by The Associated Press | News | Comments

Allergan and Pershing Square are agreeing on at least one step toward settling a fight over the makeup of the Botox-maker's board. Allergan will hold special shareholders meeting, as Pershing Square and its partner, Valeant Pharmaceuticals, continue their push for control of the drugmaker.

Advertisement

Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester, NY

September 9, 2014 8:39 am | News | Comments

Valeant Pharmaceuticals hosted a ribbon cutting ceremony for the new Bausch + Lomb ULTRA contact lens manufacturing lines and solar array assembly at the company's Optics Center in Rochester, NY. The ceremony recognized the expansion and installation of the new manufacturing lines, which will produce the company's silicone hydrogel contact lens, Bausch + Lomb ULTRA.

Allergan to Request Court Block Valeant and Pershing Square from Voting Shares Acquired in Violation of Insider Trading Laws

August 27, 2014 8:27 am | News | Comments

Allergan has asked the United States District Court for the Central District of California to set an expedited schedule for discovery and a motion for a preliminary injunction against Valeant Pharmaceuticals, Pershing Square Capital Management, L.P., and its principal, William A. Ackman, for violations of the federal securities laws.

Allergan Reviews Meeting Requests in Takeover Bid

August 23, 2014 2:27 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Allergan Inc. is reviewing shareholder requests for a special meeting to consider replacing most of its board, a change fellow drugmaker Valeant Pharmaceuticals International Inc. is seeking as part of the hostile takeover attempt it's been waging since April. Allergan has repeatedly...

Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino

August 12, 2014 8:39 am | News | Comments

Valeant Pharmaceuticals International  announced that the company has received a request for additional information from the Federal Trade Commission in connection with Valeant's proposed acquisition of Allergan, Inc.      

Allergan Sues Valeant, Claims Fraud in Buy Attempt

August 1, 2014 3:34 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Allergan Inc.'s lawsuit, filed Friday in U.S. District Court in Santa Ana, California, names as plaintiffs drugmaker Valeant Pharmaceuticals International Inc., New York investment and hedge fund firm Pershing Square Capital Management LP and its principal, William Ackerman.

Valeant Forecast Overshadows Strong Quarter

July 31, 2014 1:29 pm | by The Associated Press | News | Comments

The Canadian drugmaker now expects 2014 earnings to range between $7.90 and $8.10 per share, down from a forecast it made in April for $8.55 to $8.80 per share.               

Valeant Takes Allergan Complaints to Regulators

July 21, 2014 8:23 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals International Inc. is complaining to regulators that Botox maker and acquisition target Allergan has been making false statements about its business.             

Pershing Files Documents for Special Meeting Aimed at Ousting Allergan Directors

July 7, 2014 3:05 pm | by The Canadian Press | News | Comments

Pershing Square Capital Management has formally asked Allergan shareholders to support its bid for a special meeting to remove six directors and allow Valeant to proceed with its hostile takeover bid.        

Pershing Square Settles Lawsuit with Allergan

June 27, 2014 3:28 pm | by The Associated Press | News | Comments

Pershing Square, the investment firm run by activist investor Bill Ackman, said Friday it settled a lawsuit with Allergan, the maker of Botox, related to Allergan's poison pill plan and Pershing's $53 billion offer for the company.   

Allergan Board of Directors Rejects Unsolicited Exchange Offer from Valeant

June 23, 2014 8:23 am | News | Comments

Allergan, announced that its Board of Directors, after consultation with its independent financial and legal advisors, unanimously determined that Valeant Pharmaceuticals International, Inc.’s unsolicited exchange offer to acquire all outstanding common shares of Allergan is grossly inadequate.

Akorn Divests ECR Pharmaceuticals to Valeant

June 23, 2014 8:18 am | News | Comments

Akorn has sold its subsidiary, ECR Pharmaceuticals, to Valeant Pharmaceuticals for $41 million in cash and assumption of certain liabilities. ECR, which promotes certain branded pharmaceuticals through its sales force, was acquired through the acquisition of Hi-Tech Pharmacal.

Ackman Seeks Allergan 'Poison Pill' End Run

June 13, 2014 8:14 am | News | Comments

Bill Ackman's Pershing Square Capital Management, seeking legal cover in its $53 billion takeover bid for Allergan, filed a lawsuit to confirm that its push for a special meeting of shareholders won't trigger a defensive "poison pill" plan from the Botox maker.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading